Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Untch

Showing results (101-110 of 169) with videos related to

Pageof 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancerG Konecny, M Untch, J Arboleda, et al.
Anticancer Research|August 6, 2005
Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot studyH J Stemmler, C Salat, H Lindhofer, et al.
Cancer|May 1, 1993
Enhancement of progesterone receptor levels by interferons in AE-7 endometrial cancer cellsR Angioli, M Untch, B U Sevin, et al.
Gynecologic Oncology|March 4, 1999
Frequency of BRCA1 mutation 5382insC in German breast cancer patientsJ Backe, S Hofferbert, B Skawran, et al.
ESMO Open|May 29, 2026
Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trialP Filis, X Liu, A Matikas, et al.
The International Journal of Biological Markers|April 14, 2000
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancerA Prechtl, N Harbeck, C Thomssen, et al.
Cancer Research|November 15, 1995
Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinomaP E Andreotti, I A Cree, C M Kurbacher, et al.
Cancer|June 1, 1993
In vitro potentiation of radiation cytotoxicity by recombinant interferons in cervical cancer cell linesR Angioli, B U Sevin, J P Perras, et al.
Cancers|September 13, 2025
Ribosomal RNA Degradation (RNA Disruption) in Tumour Cells: Mechanistic Insights and Potential Clinical UtilityAmadeo M Parissenti, Sanaa Noubir, Laura B Pritzker, et al.
Seminars in Oncology|February 1, 1996
Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancerH J Luck, C Thomssen, A duBois, et al.
Pageof 17

Showing results (101-110 of 169) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancerG Konecny, M Untch, J Arboleda, et al.
Anticancer Research|August 6, 2005
Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot studyH J Stemmler, C Salat, H Lindhofer, et al.
Cancer|May 1, 1993
Enhancement of progesterone receptor levels by interferons in AE-7 endometrial cancer cellsR Angioli, M Untch, B U Sevin, et al.
Gynecologic Oncology|March 4, 1999
Frequency of BRCA1 mutation 5382insC in German breast cancer patientsJ Backe, S Hofferbert, B Skawran, et al.
ESMO Open|May 29, 2026
Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trialP Filis, X Liu, A Matikas, et al.
The International Journal of Biological Markers|April 14, 2000
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancerA Prechtl, N Harbeck, C Thomssen, et al.
Cancer Research|November 15, 1995
Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinomaP E Andreotti, I A Cree, C M Kurbacher, et al.
Cancer|June 1, 1993
In vitro potentiation of radiation cytotoxicity by recombinant interferons in cervical cancer cell linesR Angioli, B U Sevin, J P Perras, et al.
Cancers|September 13, 2025
Ribosomal RNA Degradation (RNA Disruption) in Tumour Cells: Mechanistic Insights and Potential Clinical UtilityAmadeo M Parissenti, Sanaa Noubir, Laura B Pritzker, et al.
Seminars in Oncology|February 1, 1996
Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancerH J Luck, C Thomssen, A duBois, et al.
Pageof 17